Favorable regulatory outcomes and a high demand for novel and on-demand cell and gene therapies has poised viral vector manufacturing for a significant jump. At present, availability of fully characterized, consistent and validated starting materials has posed significant limitations in this field, but new, higher throughput processes are gaining momentum, lowering material costs and increasing scalability. Historically, cell and gene therapies have been used to cure rare and ultra-rare diseases. With new efficiencies on the horizon, what does this mean for the future of these therapies and their potential to treat a wider patient population?
In this webinar, our panel of experts will discuss:
- Are autologous therapies here to stay?
- Are allogeneic therapies the future?
- The unlimited scope of gene editing technologies